Latest Conference Articles

Brexucabtagene autoleucel demonstrated similar efficacy across age groups of patients with relapsed/refractory B-cell acute lymphoblastic leukemia

Treatment with asciminib results in superior efficacy and safety vs investigator-selected TKIs in CML according to updated 96-week data from ASC4FIRST.

Single-agent, subcutaneous epcoritamab generated deep responses in patients with relapsed/refractory chronic lymphocytic leukemia.

Olverembatinib showed potential in patients with chronic-phase chronic myeloid leukemia with prior exposure to first-line second-generation TKIs.

Data from a retrospective analysis showcase the real-world effectiveness of tafasitamab for relapsed/refractory DLBCL in the United States.

FS118, an investigational LAG-3/PD-L1 bispecific antibody, demonstrated an encouraging objective response rate in the relapsed/refractory DLBCL setting.

Marcella Ali Kaddoura, MD, discusses genomic determinants of clinical outcomes in myeloma with t(11;14)(CCND1;IGH) treated with venetoclax.

Ira Zackon, MD, discusses findings on the real-world utilization of bispecific antibodies in the treatment of relapsed/refractory multiple myeloma in the community oncology setting.

Wojciech Jurczak, MD, PhD, discusses the safety and efficacy of nemtabrutinib, a noncovalent reversible BTK inhibitor in relapsed or refractory follicular lymphoma.

Revumenib plus decitabine/cedazuridine and venetoclax produced responses in relapsed/refractory acute myeloid leukemia.

Daratumumab plus VRd improved MRD responses and progression-free survival in transplant-ineligible or -deferred newly diagnosed multiple myeloma.

Revumenib demonstrated meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia.

Findings showed the potential impact of smoking on disease progression and survival in patients with myelodysplastic syndrome.

Blinatumomab plus chemotherapy significantly improved 3-year DFS rates vs chemotherapy alone in pediatric patients with standard-risk pediatric B-ALL.

Treatment with bicistronic CD19/CD22 CAR T-cell therapy led to high 1-year EFS and OS rates among children with relapsed/refractory B-ALL.

Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.

Perioperative vorasidenib or ivosidenib demonstrated sustained clinical benefit in patients with predominantly non-enhancing IDH1-mutant diffuse glioma.

Mirdametinib led to sustained, significant, and clinically meaningful improvements in HRQOL in adults and children with NF1-PN.

Priya U. Kumthekar, MD, discusses the use of a novel diagnostic platform to detect CSF tumor cells in patients with leptomeningeal disease.

David Schiff, MD, discusses PFS and OS data for radiation with or without temozolomide in patients with grade II glioma.

Larotrectinib produced rapid and durable responses and a high DCR in pediatric patients with TRK fusion–positive primary central nervous system tumors.

Timothy Gershon, MD, PhD, discusses an analysis of patients with NF1-PN who achieved deep responses with mirdametinib in the phase 2b ReNeu study.

Jordan R. Hansford, MD, discusses health-related quality-of-life outcomes with tovorafenib in pediatric patients with BRAF-altered low-grade glioma.

Updated INDIGO data reveal that vorasidenib continues to showcase improved efficacy over placebo in patients with IDH1/2-mutated diffuse glioma.

Tovorafenib generated durable drug holiday responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.

Early safety findings from the phase 2b RESTORE study (NCT03862430) of NanO2 plus radiation and temozolomide in newly diagnosed glioblastoma were shared.

J. Bradley Elder, MD, discusses blinded early-safety data from a phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma.

Rimas V. Lukas, MD, discusses the efficacy of eflornithine plus lomustine in recurrent IDH-mutant anaplastic astrocytoma per 2021 WHO diagnostic criteria.

IGV-001, an autologous cell immunotherapy, demonstrated an acceptable safety profile in patients with newly diagnosed glioblastoma.

Diane Reidy-Lagunes, MD, discusses key trials that have expanded the treatment paradigm for patients with neuroendocrine tumors.